To start off, there are three types of chronic pains, nociceptive pain, sensory hypersensitivity and neuropathic pain.  Examples of nociceptive pain are gout, rheumatoid arthritis (RA) and osteoarthritis. Fibromyalgia is sensory hypersensitivity meanwhile neuropathic pain examples are postherpetic neuralgia and diabetic peripheral neuropathy. In France, about 7 – 10 percent of the population suffers from the neuropathic pain. Furthermore, there is no productive treatment for the disease.

source: flickr | Illustration of Allodynia.

A recent research conducted by French researchers from the University of Montpellier and University of Strasbourg helps to dedramatize the situation of this chronic pain. Their study “Inhibition of neuronal FLT3 receptor tyrosine kinase alleviates peripheral neuropathic pain in mice” is published in Nature magazine during March.

From their study, experts were able to understand the surprising role of the molecule FLT3 on the chronic pain. This molecule is produced by the stem cells and is recognized for a variety of blood functions. The neuropathic pain is a result of an injury in a part of the peripheral nervous system caused by different diseases.  When the immune cells flow on the injury at the peripheral nervous system they stick the FL molecule which then activates the FLT3. This generates a backlash on the sensory neurons coupled with pain.

After this, the researchers of the study created a molecule called BDT001 which aims the injury and stops the FL molecule to bind with FLT3. This molecule was tested in animals and showed promising results like a significant reduction of pain for common neuropathic pain diseases such as allodynia and hyperalgesia. Allodynia is a chronic pain which is caused by stimuli which commonly doesn’t cause pain meanwhile hyperalgesia is an increase in the pain sensitivity. From the tests, it was also observed that the effect of the BDT001 molecule continued for about 48 hours for a dosage alone.

The creation of this new treatment is very promising knowing the fact that 4 million people in France suffer from the neuropathic chronic disease. A further support for this statement is the fact that all of the treatments which tend to treat this disease are unfortunately ineffectual. Besides the fact that these treatments, which usually are anti-depressants, cause side effects, their usage barely gives a little reduction in pain for less than 50% of the patients suffering from this disease. The start-up company Biodol Therapeutics is experimenting and is trying to create the healing treatment so that a lot of people will feel relief from the disease in the future.